DACS
PTGX icon

Dymon Asia Capital (Singapore)’s Protagonist Therapeutics PTGX Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,600
Closed -$485K – 309
2026
Q1 		$485K Sell
4,600
-5,400
-54% -$478K 0.05% 211
2025
Q4 		$873K Buy
+10,000
New +$818K 0.08% 174

Other funds holding PTGX

JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s PTGX Position: Q2 2026 in Review

Dymon Asia Capital (Singapore) sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 4,600 shares — an estimated $485K sold.

Dymon Asia Capital (Singapore) first reported a position in PTGX in Q4 2025 and held it in 2 quarters. The position peaked at $873K in Q4 2025. 121 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Dymon Asia Capital (Singapore) reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Dymon Asia Capital (Singapore) sold 4,600 Protagonist Therapeutics shares in Q2 2026, an estimated $485K.
  • Dymon Asia Capital (Singapore) first reported a position in Protagonist Therapeutics in Q4 2025 and held it in 2 quarters.
  • Dymon Asia Capital (Singapore)'s Protagonist Therapeutics position peaked at $873K in Q4 2025.
  • 121 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q2 2026, filed 23 Jul 2026.